Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Authors not listed
Brandon G. Busbee, MD · 2007
Abstract
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2007). Evaluation of Dosing Interval of Higher Doses of Ranibizumab. <em>Brandon G. Busbee, MD</em>. https://clinicaltrials.gov/study/NCT00533520
Vancouver
Anonymous. Evaluation of Dosing Interval of Higher Doses of Ranibizumab. Brandon G. Busbee, MD. 2007.
BibTeX
@misc{anon2007Evalua,
title = {Evaluation of Dosing Interval of Higher Doses of Ranibizumab},
author = {Anonymous},
journal = {Brandon G. Busbee, MD},
year = {2007},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Survey of Ophthalmology 2012
Citation only
Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Control Delivery Systems 2001
Open access · US-GOV
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
Opthea Limited 2017
Open access · US-GOV
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
American Journal of Ophthalmology 1995
Citation only
A Twin Study of Age-related Macular Degeneration
Advanced Drug Delivery Reviews 2005
Citation only
Wet age-related macular degeneration
New England Journal of Medicine 2011
Open access · OA